QURE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Uniqure NV (QURE) is not a strong buy for a beginner, long-term investor at this moment. While there are some positive catalysts, the financial performance and regulatory uncertainties make it prudent to hold off on investment until clearer signals emerge.
The technical indicators are neutral. The MACD is positive but contracting, RSI is neutral at 54.598, and moving averages are converging. The stock is trading near its pivot level of 16.575, with resistance at 18.874 and support at 14.275.
Analysts like Mizuho, RBC, and Wells Fargo have upgraded the stock recently, citing potential for regulatory approval and commercial uptake.
The company faces regulatory uncertainty, with a potential Phase 3 trial for AMT-130 that could delay progress by three-plus years. Insider and hedge fund trading trends are neutral, and there is no recent news to drive momentum.
In Q4 2025, revenue increased by 6.65% YoY to $5.57 million, but net income dropped by -49.38% YoY to -$37.09 million. EPS fell by -60.67% YoY to -0.59. Gross margin improved to 92.19%, up 4.59% YoY, but the overall financials indicate significant losses.
Analyst sentiment is mixed. Recent upgrades from Mizuho, RBC, and Wells Fargo highlight potential regulatory improvements and a positive outlook for AMT-130. However, Barclays and Chardan have expressed concerns about regulatory delays and uncertainty, leading to lower price targets.
